-
EP4048402
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4048402
| EP4048402 - MODIFIED CYTOTOXIC T CELLS AND METHODS OF USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 29.07.2022 Database last updated on 14.06.2024 | |
| Former | The international publication has been made Status updated on 03.05.2021 | Most recent event Tooltip | 19.12.2023 | The date on which the examining division becomes responsible, has been established | 19.12.2023 | Amendment by applicant | Applicant(s) | For all designated states Cue Biopharma, Inc. 40 Guest Street Boston, MA 02135 / US | [2022/35] | Inventor(s) | 01 /
SURI, Anish 21 Erie Street Cambridge, Massachusetts 02139 / US | [2022/35] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2022/35] | Application number, filing date | 20880162.1 | 22.10.2020 | [2022/35] | WO2020US56901 | Priority number, date | US201962925111P | 23.10.2019 Original published format: US 201962925111 P | [2022/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021081232 | Date: | 29.04.2021 | Language: | EN | [2021/17] | Type: | A1 Application with search report | No.: | EP4048402 | Date: | 31.08.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.04.2021 takes the place of the publication of the European patent application. | [2022/35] | Search report(s) | International search report - published on: | US | 29.04.2021 | (Supplementary) European search report - dispatched on: | EP | 24.10.2023 | Classification | IPC: | A61P31/12, A61K39/00, A61P35/00, A61P35/02, C12N15/62, C07K14/55, C07K14/725, C07K14/74, A61K39/08, A61K39/12 | [2023/47] | CPC: |
A61K39/12 (EP,IL);
A61K35/17 (EP,IL,US);
A61K38/1774 (US);
A61K39/0011 (EP,IL);
A61K39/08 (EP,IL);
A61K39/4611 (EP,IL);
A61K39/4631 (EP,IL);
A61K39/4632 (EP,IL);
A61K39/4644 (EP,IL);
A61P31/12 (EP,IL);
A61P35/00 (EP,IL);
A61P35/02 (EP,IL);
C07K14/55 (EP);
C07K14/7051 (EP);
C07K14/70539 (EP);
C12N15/625 (US);
C12N5/0638 (EP,IL,US);
C07K2319/03 (EP);
C07K2319/30 (EP);
C07K2319/31 (EP);
C12N15/62 (EP);
C12N2710/16134 (EP,IL)
(-)
|
| Former IPC [2022/35] | A61P31/12, A61K39/00, A61P35/00, A61P35/02 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/35] | Title | German: | MODIFIZIERTE ZYTOTOXISCHE T-ZELLEN UND VERFAHREN ZUR VERWENDUNG DAVON | [2022/35] | English: | MODIFIED CYTOTOXIC T CELLS AND METHODS OF USE THEREOF | [2022/35] | French: | LYMPHOCYTES T CYTOXIQUES MODIFIÉS ET LEURS PROCÉDÉS D'UTILISATION | [2022/35] | Entry into regional phase | 15.02.2022 | National basic fee paid | 15.02.2022 | Search fee paid | 15.02.2022 | Designation fee(s) paid | 15.02.2022 | Examination fee paid | Examination procedure | 15.02.2022 | Examination requested [2022/35] | 19.12.2023 | Amendment by applicant (claims and/or description) | 19.12.2023 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 15.09.2022 | Renewal fee patent year 03 | 13.09.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2018119114 (CUE BIOPHARMA INC [US]) [A] 1-15 * Whole document, especially the claims and §00240. *; | [A]WO2019162937 (TECHNION RES & DEV FOUNDATION [IL]) [A] 1-15 * Whole document, especially the claims *; | [A] - CARD K F ET AL, "A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity", CANCER IMMUNOLOGY IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, (20040401), vol. 53, no. 4, doi:10.1007/S00262-003-0450-3, ISSN 0340-7004, pages 345 - 357, XP002351550 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1007/s00262-003-0450-3 | [A] - WU CHIA-YUNG ET AL, "Remote control of therapeutic T cells through a small molecule-gated chimeric receptor", SCIENCE, US, (20151016), vol. 350, no. 6258, doi:10.1126/science.aab4077, ISSN 0036-8075, XP055853676 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1126/science.aab4077 | International search | [Y]WO9400150 (HOPE CITY [US], et al) [Y] 1-8 * Abstract; Claim 1; p6, para 1; p6, para 3; p7, para 2; p9, para 2 *; | [Y]US2017335281 (LOEW ANDREAS [US], et al) [Y] 1-8* Abstract; Claim 17; Claim 26; Claim 27; para [0004]; para [0072]; para [0891] * |